“The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr. Degatano.
NEW YORK (PRWEB) April 09, 2020
AllazoHealth, a company that uses artificial intelligence to help pharmaceuticals, payers, and pharmacies improve medication adherence and quality outcomes, announced today that pharmaceutical industry veteran Mark Degatano will be joining the company’s Advisory Board. Mr. Degatano has over 35 years of industry experience spanning client, vendor and start-up areas. He currently serves on the advisory boards of several innovative providers in the pharmaceutical industry, and is a leader in developing and commercializing data-based solutions to help companies improve brand performance and grow sales.
"Mark brings a wealth of experience in the pharmaceutical space and with analytics that is incredibly aligned with the value that AllazoHealth provides to the market,” commented Devraj Mukherjee, Vice President of Business Development for AllazoHealth. “We're looking forward to leveraging Mark’s experience to continue on our growth trajectory."
Prior to joining the AllazoHealth advisory board, Mr. Degatano’s professional background included 24 years with Merck where he rose to Vice President of Customer Insights. He was previously Chief Operating Officer of ComSort Inc., a healthcare data analytics company. In addition, he has worked at numerous data and service providers, including Symphony Health, Prognos, IQVIA, and Aptus Health.
“The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr. Degatano. “I’m confident my experiences on the client and solutions sides will help the company more effectively express the great value their AI capabilities bring to brand performance, and ultimately improves patient engagement.”
According to Mr. Degatano, while many suppliers talk "AI", very few can actually demonstrate how it benefits brand marketers. “This shortfall is especially true in the increasingly important ability to drive patient engagement. Over the next few years, there will be a greater focus on AI-based solutions that actually achieve their patient engagement goals. This is where AllazoHealth is already making a significant improvement on behalf of its clients,” he concluded.
Mr. Degatano holds a B.A. in mathematics and an M.A. in statistics, both from Boston University. He is joining AllazoHealth’s advisory board effective immediately.
To learn more about AllazoHealth, please visit http://www.allazohealth.com or email email@example.com